PHASE 2 STUDY OF ZW25 PLUS FIRST-LINE COMBINATION CHEMOTHERAPY IN HER2-EXPRESSING GASTROESOPHAGEAL ADENOCARCINOMA (GEA)
- Registry ID
- ZWI-ZW25-201
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- JAZZ PHARMACEUTICALS IRELAND LIMITED
- Start date
- 2019-08-15
- Last update
- 2018-12-20
Conditions
- GASTROESOPHAGEAL ADENOCARCINOMA
- GASTRO-OESOPHAGEAL CANCER
Related clinical trials
- AACR ADAPTIVE BIOMARKER-DRIVEN ORGAN PRESERVATION TRIAL IN GASTROESOPHAGEAL ADENOCARCINOMAS
- ROSETTA GASTRIC-204: A BLINDED, RANDOMIZED, PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
- A PHASE III, MULTICENTRE, RANDOMISED CONTROLLED STUDY OF SONESITATUG VEDOTIN IN
COMBINATION WITH FLUOROPYRIMIDINE WITH OR WITHOUT RILVEGOSTOMIG IN FIRST-LINE
CLAUDIN18.2-POSITIVE, HER2-NEGATIVE, ADVANCED/METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
(CLARITY-GASTRIC 02)
- A MASTER PROTOCOL FOR AN OPEN-LABEL, MULTI-DRUG, MULTI-CENTER,
PHASE II PLATFORM STUDY TO EVALUATE THE SAFETY, TOLERABILITY,
PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF NOVEL
AGENTS OR COMBINATIONS AS PERIOPERATIVE TREATMENT IN PARTICIPANTS
WITH LOCALLY ADVANCED RESECTABLE GASTROESOPHAGEAL
ADENOCARCINOMA (GEMINI-PERIOP GC)
- BEAMION PANTUMOR-1: A PHASE II, MULTICENTRE, MULTICOHORT, OPEN LABEL
TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZONGERTINIB (BI 1810631) FOR THE
TREATMENT OF SELECTED HER2-MUTATED OR OVEREXPRESSED/AMPLIFIED SOLID TUMOURS
- A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY
AND SAFETY OF MK-2870 VERSUS TREATMENT OF PHYSICIAN¿S CHOICE IN 3L+
ADVANCED/METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA (GASTRIC
ADENOCARCINOMA, GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, AND ESOPHAGEAL
ADENOCARCINOMA)
View on source registry